Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
Real-time Quote. Real-time Tradegate - 08/23 02:44:33 am
68.35 EUR   +0.93%
08/22EXPLAINER : What are the obstacles to Bayer settling Roundup lawsuits?
RE
08/21NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/21NEWS HIGHLIGHTS : Top Company News of the Day
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Explainer: What are the obstacles to Bayer settling Roundup lawsuits?

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2019 | 10:07am EDT
Logo of Bayer AG at a plant of the German pharmaceutical and chemical maker in Wuppertal

(Reuters) - Bayer AG is in mediation to potentially settle thousands of U.S. lawsuits claiming that the company's Roundup weed killer causes cancer, but some legal experts said the cases raises novel questions that may prevent an easy settlement.

More than 18,400 plaintiffs claim Roundup causes a type of cancer called non-Hodgkin's lymphoma.

Bayer to date has lost three U.S. jury trials in the Roundup litigation. The company is appealing the decisions, saying Roundup and its active ingredient glyphosate are not carcinogenic and safe for human use.

On July 30, Bayer said it is "constructively engaging" in talks led by mediator Ken Feinberg. Bayer's chief executive said he would only consider a "financially reasonable" settlement if the company can end all litigation.

Feinberg said mediation was still in the early stages and compensation had not been discussed.

Bayer declined to comment, citing confidentiality agreements in the mediation. Plaintiffs lawyers did not respond to requests for comment.

Legal experts outlined several obstacles the parties may face on the path towards settlement.

WHY IS THE ROUNDUP LITIGATION DIFFERENT FROM OTHER PRODUCT CASES?

Settlements involving drugs, medical devices or consumer goods often result in the addition of a warning label, a recall or the outright discontinuance of a product. Those steps generally close the door to future lawsuits, making settlement costs and risks predictable.

Bayer has never publicly considered pulling Roundup off the market. The company in June announced a $5.6 billion (£4.6 billion) investment to research and develop a glyphosate alternative.

Bayer unit Monsanto began selling Roundup in 1974 and while the formulation is no longer patent-protected, Roundup remains widely available today. Bayer has repeatedly said Roundup is safe and important to farmers who use the herbicide in combination with the company's genetically modified seeds

Non-Hodgkin's lymphoma on average can take up to 10 years to emerge, increasing the likelihood of claims being filed after the litigation has settled. Product liability settlements generally include a cut-off date for future claimants and need to be properly funded for a court to approve the agreement.

As long as the product continues to be sold without changes to the label, plaintiffs may continue to file lawsuits, said Elizabeth Burch, a law professor at the University of Georgia.

COULD BAYER ADD A CANCER WARNING?

Plaintiffs lawyers, who claim the company manipulated the science, told Reuters they would insist on a cancer warning label as part of any Roundup settlement.

Such a warning has been rejected by the U.S. Environmental Protection Agency, which regulates pesticides and repeatedly has found glyphosate to be safe.

The agency in an Aug. 7 letter said any glyphosate cancer warning constitutes "a false and misleading statement," and ordered California, the only U.S. state requiring such a warning, to remove the label.

David Noll, a professor at Rutgers Law School, said adding a cancer warning over a regulator's explicit opposition presented unchartered legal territory.

HOW COULD BAYER SETTLE THE ROUNDUP LITIGATION?

To settle product liability litigation, companies generally set up a fund and the parties define criteria that current and future claimants must fulfil to receive compensation.

In the Roundup litigation, claimants could be divided into different groups depending on the frequency of their Roundup use and disease severity and length.

But Adam Zimmerman, a law professor at Loyola Law School, said defining those groups is complicated by the lack of a signature disease associated with Roundup, making it difficult to predict Bayer's liability.

For example, in asbestos litigation, mesothelioma, a rare tissue cancer, was recognised as a signature disease caused by exposure to asbestos fibres.

Doctors recognise several risk factors leading to non-Hodgkin's lymphoma, but the disease is largely considered to have no known cause. Around 74,000 people in the United States are expected to be diagnosed with the disease in 2019, according to the American Cancer Society.

Settling claims might not preclude future lawsuits if the fund runs out of money. In the Agent Orange litigation, Vietnam War veterans were allowed to sue chemical companies decades after a settlement was reached because the compensation fund was depleted by the time they developed their diseases.

(Reporting by Tina Bellon in New York; Editing by Noeleen Walder, Anna Driver and Lisa Shumaker)

By Tina Bellon

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
08/22EXPLAINER : What are the obstacles to Bayer settling Roundup lawsuits?
RE
08/21NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/21NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/21NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/21Bayer Sells Pet-Health Unit for $7.6 Billion -- WSJ
DJ
08/20Health Care Lower as Litigation, Deal Risks Linger -- Health Care Roundup
DJ
08/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/20ELANCO ANIMAL HEALTH : Bayer to sell its Animal Health business unit to Elanco f..
AQ
More news
Financials (EUR)
Sales 2019 46 207 M
EBIT 2019 8 344 M
Net income 2019 3 161 M
Debt 2019 37 472 M
Yield 2019 4,20%
P/E ratio 2019 20,7x
P/E ratio 2020 14,4x
EV / Sales2019 2,18x
EV / Sales2020 2,06x
Capitalization 63 414 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 78,57  €
Last Close Price 68,00  €
Spread / Highest target 80,9%
Spread / Average Target 15,5%
Spread / Lowest Target -43,0%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG11.82%70 311
JOHNSON & JOHNSON1.72%347 129
ROCHE HOLDING LTD.12.16%238 668
MERCK AND COMPANY13.49%222 522
NOVARTIS17.97%206 833
PFIZER-20.11%192 868